InSitu Biologics

InSitu Biologics

InSitu Biologics

AnestaGel is a longlasting and longacting nonopiate painkiller, targeted for use in perioperative regional pain management.
Raised
$2M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$2,000,000
Venture capital - 2018
Team Size
1–10
Employees
$2,000,000 Venture capital
FinSMEs

InSitu Biologics Raises Over $2M in Funding